William French, MD - Anticoagulation: Special Populations - Figure 3

ROCKET AF: Primary Endpoint

This Figure shows the differential increase in risk of stroke or systemic embolism in just the first 6 years following entry into the ROCKET AF trial for patients aged <75 years compared with patients aged ≥75 years.[121] The curves for the primary endpoint show the benefit of treatment with the novel oral anticoagulant (NOAC), rivaroxaban (dark blue lines), versus treatment with warfarin (red lines), but in addition, there is a larger benefit in the older patients (right panel vs left panel). The principal point of these curves, however, is the rapid increase in risk across an age increase of just 6 years in all patients.

French WJ. Am J Med 2013; 126: 00-00.

[ROCKET AF = Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation]

Complete references for all slides

References

[121] Patel MR, Mahaffey KW, Garg J, et al; the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.